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Available online 9 June 2016Whereas positron emission tomography (PET)with the antagonist ligand [18F]fallypride reveals the composite of
dopamine D2 and D3 receptors in brain, treatment of Parkinson's disease (PD) patients with the D3-prefering ag-
onist pramipexole should result in preferential occupancy in the nucleus accumbens, where the D3-subtype is
most abundant. To test this prediction we obtained pairs of [18F]fallypride PET recordings in a group of nine PD
patients, ﬁrst in a condition of treatment as usual with pramipexole (ON-Sifrol; 3 × 0.7 mg p.d.), and again at a
later date, after withholding pramipexole 48–72 h (OFF-Sifrol); in that condition the serumpramipexole concen-
tration had declined by 90% and prolactin levels had increased four-fold, in conjunction with a small but signif-
icant worsening of PD motor symptoms. Exploratory comparison with historical control material showed 14%
higher dopamine D2/3 availability in the more-affected putamen of patients OFF medication. On-Sifrol there
was signiﬁcant (p ˂ 0.01) occupancy at [18F]fallypride binding sites in globus pallidus (8%) thalamus (9%) and
substantia nigra (19%), as well as marginally signiﬁcant occupancy in frontal and temporal cortex of patients.
Contrary to expectation, comparison of ON- andOFF-Sifrol results did not reveal any discernible occupancy in nu-
cleus accumbens, or elsewhere in the extended striatum; presentmethods should be sensitive to a 10% change in
dopamine D2/3 receptor availability in striatum; the signiﬁcant ﬁndings elsewhere in the basal ganglia and in ce-
rebral cortex are consistent with a predominance of D3 receptors in those structures, especially in substantia
nigra, and imply that therapeutic effects of pramipexole may be obtained at sites outside the extended striatum.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Occupancy1. Introduction
Levodopa and direct agonists at striatal dopamineD2/3 receptors are
the mainstay treatment for motor symptoms of Parkinson's disease
(PD). Among the most important dopamine agonists in clinical practice
are the benzothiazole pramipexole, the dipropylaminoethyl indole
ropinirole, its thiophen homologues rotigotine, piripedil, and the
dibenzoquinoline apomorphine; all of these medications are character-
ized by partial selectivity for D3 over the more abundant D2 receptors.
In the case of pramipexole, this preference is reported to be as high as
100-fold in favor of D3 receptors (Millan et al., 2002). At least in rodent
models of PD, pramipexole is neuroprotective against nigrostriatalCounselling, Faculty of Health,
pus, O Block - B wing - Level 5,
ng).
. This is an open access article underdegeneration (Joyce et al., 2004; Lao et al., 2013, Kim et al., 2015), al-
though there is little evidence of disease-modifying effects of treatment
of PD patients with pramipexole (Schapira et al., 2013), or conversely
that levodopa exacerbates disease progression (Fahn, 2005). Nonethe-
less, clinical use of pramipexole and other direct agonists is favored in
younger patients with PD (b70 years), and pramipexole in particular
is considered to have an antidepressant effect in PD patients (Barone
et al., 2010), in addition to its alleviation ofmotor symptoms, suggesting
a particular link between D3 receptor activation and favorable treat-
ment responses.
On the other hand, treatmentwith dopamine agonists, and to a less-
er extent also levodopa, can evoke a variety of undesirable neuropsychi-
atric side-effects, including sleepiness and visual illusions, as well as
delusions; one study reports that pramipexole is more likely than
other agonists to evoke hallucinations and confusion (Kulisevsky and
Pagonabarraga, 2010). Pramipexole and other direct agonists have
been particularly implicated in iatrogenic impulse control disorders,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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eating. In one study of nearly 200 PD patients taking oral pramipexole,
42% developed impulse control disturbances (Garcia-Ruiz et al., 2014),
versus 14% in a larger cross-sectional study (Weintraub et al., 2010). In-
deed, preclinical studies show an effect of pramipexole in the probabilis-
tic discounting paradigm, which is an index of risk-taking (Rokosik and
Napier, 2012). Similarly, in a functional fMRI study of healthy young
adults, pramipexole enhanced the BOLD signal change in the nucleus
accumbens associated with anticipation of monetary reward, whilst
reducing the apparent top-down regulation by the prefrontal cortex
(Ye et al., 2011).
Autoradiographic studies of human brain indicate that D3 receptors
predominate over D2 receptors in the basal forebrain and in the
striosome compartment of the nucleus accumbens, are of intermediate
proportion in the ventral putamen, but comprise b10% of D2/3 recep-
tors in the caudate nucleus (Murray et al., 1994); the occurrence of
this dorsal-ventral gradient of D3 distribution in human brain is con-
ﬁrmed by positron emission tomography (PET) displacement studies
using the D3-prefering agonist [11C]-PHNO (Narendran et al., 2006).
Recent autoradiographic studies in transgenic D2-knockout mice con-
ﬁrmed that D3-sites normally contribute to approximately 20% of the
binding of the D2/3 antagonist ligand [18F]fallypide in ventral striatum,
but are nearly absent in dorsal striatum (Mukherjee et al., 2015).
Given the apparent proclivity of pramipexole to inﬂuence reward
and salience, and given its particular afﬁnity for the D3 receptors in
the limbic striatum, it is a matter of interest to determine the therapeu-
tic occupancy of pramipexole at its targets in human brain. Indeed, im-
pairment of impulse control in Parkinson's disease patients has recently
been attributed to the D3-agonist selectivity of pramipexole (Seeman,
2015). Competition binding assays by PET afford estimates of the thera-
peutic occupancy for CNS drugs, which have proven informative in the
case of antipsychotic medications for the treatment of schizophrenia.
Such studies established the concept of therapeutic occupancy window
at dopamine D2/3 receptors for obtaining antipsychotic efﬁcacy (b65%;
Farde et al., 1988)without provoking extrapyramidal side effects,which
typically occur when blockade exceeds 80% (Kapur et al., 1995). This
competition paradigm has since been extended to PET studies of anti-
psychotic occupancies at multiple receptor types, in support of the con-
cept of atypicality (Mamo et al., 2007), and to measuring antipsychotic
occupancy at the relatively less abundant extra-striatal dopamine D2/3
receptors (Vernaleken et al., 2008). However, hardly anything is known
about the converse case, i.e. therapeutic occupancy of dopamine recep-
tor agonists in the treatment of PD; oral treatment with the dopamine
agonist lisuride at an effective antiparkinsonian dose (1 mg p.d.)
displaced 19% of [11C]raclopride binding in the putamen of PD patients
(Antonini et al., 1994), whereas in another study, a low dose of the
agonist apomorphine (0.03 mg/kg) decreased [11C]raclopride binding,
by 9% in the more intact putamen, and by 15% on the side contralateral
to the main symptoms, suggesting an increase in afﬁnity state in the
dopamine-denervated striatum (de la Fuente-Fernández et al., 2001). A
[11C]FLB-457 PET study of ﬁve healthy middle-aged volunteers showed
10–20% occupancy at extra-striatal D2/3 receptors after challenge with
0.25 mg pramipexole (Ishibashi et al., 2011), but striatal binding could
not be calculated with that ligand.
In the present study we undertook to measure dopamine D2/3
receptor availability in striatum and extrastriatal regions of pa-
tients with idiopathic PD using the high afﬁnity antagonist ligand
[18F]fallypride, which is equally afﬁne atD2 andD3 sites (Mukherjee et
al., 2015). We predicted that receptor availability should be higher
at medication-free baseline than under treatment as usual with
pramipexole, and tested our hypothesis that occupancy by pramipexole
should be higher in the limbic striatum and extra-striatal regions than
in the putamen and caudate nucleus, in proportion to the relative abun-
dance of D3 sites. In an exploratory study, we also assessed disease and
treatment effects by comparison with historical [18F]fallypride PET data
from a healthy age-matched control group.2. Methods
Nine patients with PD were recruited from the Department of
Neurology, Ludwig-Maximilians University, Munich and from the Max
Planck Institute of Psychiatry, Munich. Nine healthy control subjects
were selected as an historical control group (Rominger et al., 2012;
Jansen et al., 2014) so as to obtain optimal age- and demographic
matching. Subjects were excluded if they had any history of substance
abuse or other psychiatric disorders or any serious medical condition
(other than PD) requiring treatment with CNS medications. The study
protocol was approved by the local clinical institutional review board
and complied with the declaration of Helsinki. Written informed
consent was obtained from all participants after the procedures had
been fully explained. Healthy volunteers had a single [18F]fallypride
scan at the Department of Nuclear Medicine. Patients had a baseline
scan at 48–72 h after cessation of pramipexole treatment and a second
[18F]fallypride PET scan two weeks later, while under treatment with
pramipexole as usual.
[18F]Fallypride was synthesized as described previously (Rominger et
al., 2010). A 15-minute transmission scan with a rotating [68Ge] point
source was followed by a 3-hour dynamic 3D emission recording, initiat-
ed immediately upon beginning the administration of [18F]fallypride
(mean dose 250 MBq) as a slow intravenous bolus. The dynamic record-
ing consisted of 39 time frames (3 × 20 s, 3 × 1min, 3 × 2min, 3 × 3min,
21 × 5min, 2 × 8min and 4 × 10min; 180 min in total), which were re-
cordedwith an ECAT EXACTHR+PET (Siemens/CTI, Knoxville, TN, USA).
During emission and transmission scans, the subjects' heads were com-
fortably immobilized within the aperture using a foam cushion. The
tomograph acquired 63 contiguous transaxial planes, simultaneously cov-
ering 15.5 cm in the axial ﬁeld of view, with 4.0 mm centre of ﬁeld reso-
lution (full width at half maximum). Dynamic image data were
reconstructed as 128 × 128 matrices of 2.1 × 2.1 × 2.4 mm voxels by
3D ﬁltered back-projection using a Hann ﬁlter with a cut-off frequency
of 0.5 Nyquist units. Final data were corrected for decay, randoms, dead
time and scatter. Emission recordings were checked for motion between
fraqmes, and then registered and normalized to an in-house standard
brain [18F]fallypride template in MNI coordinates using the SPM5
routines (WellcomeDepartment of CognitiveNeurology, London,UK) im-
plemented in MATLAB (version 7.1, MathWorks Inc., Natick, MA, USA).
Details of the image analysis procedure are reported elsewhere
(Rominger et al., 2012; Cumming et al., 2013). The sum of frames 9 to
13 (8–19min)was used as source image for normalization the individual
PET image using the SPM coregistration and normalization procedures.
We then applied a cerebellum template (excluding the vermis) to the dy-
namic volumes using the program amide (http://amide.sourceforge.net)
to calculate the time-activity-curve of the reference region. Using PMOD
(PMOD technologies, Zurich, Switzerland) we then calculated voxelwise
parametric maps of the [18F]fallypride binding potential (BPND), using a
linear graphicalmethod (Logan et al., 1996) relative to cerebellum, as pre-
viously described for [18F]fallypride (Mukherjee et al., 2002). Templates
for caudate nucleus, posterior and anterior putamen, nucleus accumbens,
thalamus, globus pallidus, insular and temporal cortex and the pituitary
gland, were applied to the individual parametric maps in order to obtain
the mean BPND by region. We used an in-house template for the striatum
and its subdivisions (la Fougère et al., 2010) and theWake Forrest Univer-
sity Pick Atlas for other regions (Maldjian et al., 2003).
[18F]Fallypide PET scans were obtained from nine neurologically
normal control subjects of mean (SD) age 63 ± 6 years who had partic-
ipated in earlier studies (Rominger et al., 2012; Jansen et al., 2014). In an
exploratory study, the spatially normalizedmeanparametricmaps from
the patients with PD (OFF condition) and the healthy control group
were compared (subtraction analysis). The threshold for signiﬁcant
difference was arbitrarily set at 0.5 units of BPND. For statistical compar-
isons with predictable outcomes (i.e. UPDRS III scores and prolactin
levels would increase in the OFF condition) we used the Student's 1-
tailed t-test
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The nine patients (7 male) were of mean (±SD) age 65 ± 6 years,
and had a diagnosis of PD since 6 ± 3 years. Five were receiving
pramipexole monotherapy (3 × 0.7 mg), and four received additional
levodopa (from 100 mg to 400 mg per day). The baseline PET scans
(ON) was obtained under conditions of pramipexole medication as
usual (pramipexole 3 × 0.7 mg), except that the patients who addition-
ally took levodopa withdrew for 18 h before the scan. Scanning was al-
ways performed at 11:30 a.m. Two weeks later, the second PET scan
(OFF) was obtained after pramipexole had been paused for 48–60 h;
again, levodopa was paused for 18 h before the scan. Medication as
usual was resumed after conclusion of the second PET recording in
each patient.
The mean UPDRS III score was 11.3 ± 4.8 in the ON condition, and
deteriorated signiﬁcantly to 15.0 ± 3.0 in the OFF condition (p =
0.008). Mean prolactin levels increased from 13 ± 7 IU/ml in the ON
condition to 65 ± 39 IU/ml in the OFF condition (n = 7; p = 0.008).
Plasma pramipexole levels declined from 2590 ± 870 (range 910–
3960) ng/l in the ON condition to 300 ± 240 (range 186–689) ng/l in
the OFF condition (p= 0.00002), showing a strong negative correlation
between individual pramipexole and prolactin levels (R = −0.81:
p b 0.001).
Mean parametric maps ON and OFF pramipexole (Fig. 1) are
depicted with ﬂipping of images so that the left cerebral hemisphere
is contralateral to themainmotor symptoms. There is nodiscernible dif-
ference by condition in the mean BPND anywhere in the extendedFig. 1.Mean parametricmaps of [18F]fallypride BPND in a group of nine patientswith Parkinson's
signiﬁcantly alleviating motor symptoms (middle row). The insets show the results in substan
required for depiction of striatal binding). An exploratory voxelwise subtraction of the mean
(bottom row) show a zone in the left striatum (i.e. contralateral to body side with main symp
increase in that volume corresponded 14% relative to the control group.striatum, although a reduction in availability was clearly discernible in
the substantia nigra (insets), when the color scale was restricted for
visualization of the much lower binding. Examination of individual
parametric maps suggested that patients had relatively greater striatal
volume loss and more pronounced ventricular dilation than did the
age-matched controls. In the absence of individual MR images, registra-
tion and normalization procedures tended to result in misalignment of
the VOI template set, such that binding results between patients and
controls were not directly comparable. However, the exploratory
voxelwise subtraction revealed a zone in the left (more affected) puta-
men where BPND in the patients scanned OFF pramipexole exceeded
that in the healthy controls by at least 0.5 units; the mean magnitude
of BPND the correspondingmasked region was 10.5 ± 1.5 in the healthy
controls, suggesting a 14% increase in dopamineD2/3 availability on the
more-affected side in patients OFF medication.
VOI analysis revealed no signiﬁcant left-right differences in the
regional [18F]fallyprideBPND, either at Scan1 or Scan 2, irrespective ofﬂip-
ping the maps, so that main motor symptoms were contralateral to the
left cerebral hemisphere; for simplicity, we therefore report the mean
BPND measurements for bilateral structures in Table 1. Based on the hy-
pothesis that [18F]fallypride BPND should decrease ON pramipexole, the
1-tailed t-test showed signiﬁcant decreases in bilateral globus pallidus
(8%; p = 0.007), thalamus (9%; p = 0.002) substantia nigra (19%; p =
0.0004), as well as frontal cortex (28%; p = 0.043) and temporal cortex
(9%; p= 0.023). There were no signiﬁcant correlations between individ-
ual estimates of occupancy (BPND changes between scans) and level of
pramipexole or prolactin OFF medication (data not shown).disease scannedOFFmedication (upper row) andONpramipexolemonotherapy, at a dose
tia nigra, with the BPND color scale restricted to the range 0–1.5 units (rather than 0–25 as
OFF medication condition and results from the historical age-matched healthy controls
toms) in which BPND exceeded that in the healthy controls by at least 0.5 units; the mean
Table 1
The binding potential (BPND) for [18F]fallypride in various brain regions in a group of
Parkinson's disease patients aged 67 ± 6 years. The patients were scanned during their
regular pramipexole treatment (ON, Scan 1) and after withdrawal for 48–72 h (OFF, Scan
2). Each result is the mean (±SD) of determinations in nine subjects. There were signiﬁ-
cant differences between the ON and OFF conditions in thalamus, frontal cortex and tem-
poral cortex. Occupancies in theONcondition are estimated from the reduction inBPNDON
pramipexole relative to that OFF pramipexole.
ON pramipexole OFF pramipexole
Caudate nucleus 10.4 ± 1.1 (2 ± 5%) 10.3 ± 1.3
Putamen, anterior 16.9 ± 1.1 (1 ± 5%) 17.1 ± 1.3
Putamen, posterior 11.4 ± 0.9 (3 ± 6%) 11.8 ± 1.3
Nucleus accumbens 8.6 ± 1.4 (1 ± 5%) 8.7 ± 1.3
Globus pallidus 5.5 ± 2.3 (8 ± 6%; p = 0.007) 5.9 ± 2.0
Substantia nigra 1.04 ± 0.35 (19 ± 12%; p = 0.0004) 1.24 ± 0.29
Thalamus 0.88 ± 0.25 (9 ± 6%; p = 0.002) 0.96 ± 0.04
Hippocampus 0.57 ± 0.20 (0 ± 0%) 0.59 ± 0.21
Amygdala 1.61 ± 0.67 (5 ± 12%) 1.72 ± 0.72
Frontal cortex 0.12 ± 0.07 (28 ± 31%; p = 0.043) 0.14 ± 0.05
(p = 0.043)
Temporal cortex 0.29 ± 0.12 (9 ± 23%; p = 0.023) 0.32 ± 0.13
Pituitary gland 1.20 ± 0.43 (7 ± 28%) 1.34 ± 0.37
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Our main ﬁnding was the discovery of signiﬁcant therapeutic occu-
pancy by pramipexole at [18F]fallypride binding sites in bilateral globus
pallidus, thalamus substantia nigra, and in the temporal and frontal
cortex; contrary to expectation, there was no discernible occupancy in
nucleus accumbens, or elsewhere in the extended striatum. Our ﬁnding
of 9% occupancy by pramipexole at thalamic dopamine D2/3 sites, is
consistent the distribution of binding sites for the D3-prefering agonist
[11C]-PHNO (Narendran et al., 2006), and concurs closely with the 10–
20% displacement of [11C]FLB 457 in human thalamus by acute
pramipexole challenge (Ishibashi et al., 2011). Our thalamus VOI
encompasses the entire thalamus, thus reﬂecting [18F]fallypride binding
not just in motor structures (ventrolateral and ventro-anterior
thalamus), but also in sensory thalamus. The relevance of this occupan-
cy by thalamic pramipexole is uncertain, since post mortem investiga-
tion shows that the dopamine content of thalamus is relatively
preserved in idiopathic PD (Gerlach et al., 1996). Therewas a 17% reduc-
tion in [11C]FLB-457 binding to thalamic D2/3 receptors in patients with
advanced PD (Kaasinen et al., 2000, 2003), but similar thalamic de-
creases have also been seen in a meta-analysis of studies of schizophre-
nia (Kambeitz et al., 2014).We can only speculate that present ﬁndings
may imply a rectiﬁcation by pramipexole of sensorimotor deﬁcits relat-
ed to impaired thalamic dopamine signalling in PD patients.
We found 8% occupancy by therapeutic pramipexole in the globus
pallidus, with the caveat that [18F]fallypride BPND in that brain region
might be vulnerable to spill-over arising in the adjacent putamen. How-
ever, the absence of discernible occupancy in putamen, where BPND is
highest, suggests thatwehave observed a real occupancyby therapeutic
pramipexole at dopamine D2/3 receptors in globus pallidus. In a previ-
ous [11C]PHNO study in healthy volunteers with pharmacological
dopamine depletion, increasing (D3) receptor availability in globus
pallidus correlated with scores in a self-report of vigor (Caravaggio et
al., 2014). The present data are thus consistentwith a therapeutic action
of pramipexole through activation of D3 receptors in the globus pallidus
of PD patients.
The most highly pronounced difference in [18F]fallypride binding to
emerge in this studywas in the substantia nigra, where pramipexole oc-
cupancy was approximately 19%. While [18F]fallypride BPND is of low
magnitude in substantia nigra (i.e. Slifstein et al., 2010), the contrast be-
tween ON and OFF pramipexole was highly signiﬁcant (p = 0.0004),
and would survive muchmore stringent statistical criteria. This is nota-
ble given the exclusive D3 nature of [18F]fallypride binding expected in
that region based on studies cited above, and also considering the seda-
tive property of low dose pramipexole, which may preferentially act atpresynaptic autoreceptors, i.e. in the substantia nigra, to attenuate dopa-
mine release (McCormick et al., 2015). Earlier [11C]PHNO PET observa-
tions of elevated D3 binding in the substantia nigra of pathological
gamblers (Boileau et al., 2013) and increased displacement of D3 bind-
ing in substantia nigra of PD patients during performance of a gambling
task (Boileau et al., 2014; Ray et al., 2012), call for further consideration
of the effects of pramipexole treatment on the functional state or occu-
pancy at somatodendritic autoreceptors in the substantia nigra. This
may prove to be especially interesting in relation to the reports of
impulse control disorders in PD patients treated with pramipexole
(Seeman et al., 2015), and in consideration of the somewhat ambiguous
role of D3 receptors in autoreceptor regulation in the substantia nigra
(Koweltzow et al., 1998).
We have previously reported preferential blockade of cortical
[18F]fallypride binding by the rather non-selective antagonist
quetiapine (Vernaleken et al., 2010), and now report therapeutic occu-
pancy of an agonist at cortical dopamine D2/3 receptors. We concede
that the pramipexole occupancies (28% in frontal cortex and 9% in tem-
poral cortex) are imprecise, in keeping with the relatively high covari-
ance of our methods for quantitation of the low abundance cortical D2/
3 receptors (Rominger et al., 2012). Present ﬁndings in cerebral cortex
are in any event exploratory, since our hypothesis centred on occupancy
in the limbic striatum. Nonetheless, we see a good concordance with the
10% displacement of D2/3 binding in frontal cortex of healthy volunteers
by acute pramipexole in a PET study with [11C]FLB-457 (Ishibashi et al.,
2011), which is arguably a ﬁtter tracer for detecting cortical D2/3 recep-
tors (Narendran et al., 2013) Pharmacology studies indicate that the do-
pamine autoreceptors controlling dopamine release from human
neocortex slices are of the D2 type (Fedele et al., 1999), although this ac-
tion is attributed to D3 receptors in frontal cortex of behaving rats
(Gobert et al., 1996). While the proportion of D2 and D3 sites in human
cerebral cortex remains unknown, a recent review has drawn attention
to procognitive effects of D3 agonists, and suggested amechanismmedi-
ated by enhanced acetylcholine release speciﬁcally in prefrontal cortex
(Nakajima et al., 2013). Given the frequent occurrence of executive func-
tion deﬁcits in patients with PD, present ﬁndings could implicate frontal
cortex in the therapeutic action of pramipexole.
Contrary to expectationwe did not detect any discernible occupancy
in the nucleus accumbens, or elsewhere in the extended striatum; our
earlier test-retest ﬁndings predicted that we should have had sufﬁcient
power to detect a 10% decline in [18F]fallypride BPND in striatum
(Rominger et al., 2012), similar in magnitude to the effects reported
earlier in [11C]raclopride PET studies in healthy pigs treated with LSD,
inter alia, a dopamine agonist (Minuzzi et al., 2005) or in PD patients
treated with a challenge dose of lisuride (1 mg: Antonini et al., 1994),
or apomorphine (0.03 mg/kg; de la Fuente-Fernández et al., 2001). In-
deed the apomorphine challenge study reported more extensive occu-
pancy in the striatum contralateral to the main motor symptoms,
suggesting a certain sensitization of agonist binding in themore severe-
ly dopamine denervated striatum, as is likewise reported in rat lesion
studies (Palner et al., 2011). This phenomenon may have contributed
to the14% increase in [18F]fallypride binding in part of theputamen con-
tralateral to the most symptomatic side, calculated relative to the age-
matched healthy control group. Such increases are not always evident
in patients with long-standing PD (Knudsen et al., 2004), but may be a
transient feature of early disease, or in this case related to pause of
medication.
Pharmacological displacement studieswith theD3-selective antago-
nist GSK598809 in healthy volunteers indicated that 0% of [11C]-PHNO
binding was to D3 receptors in dorsal striatum, versus 25% in ventral
striatum, 50% in thalamus, and 100% in substantia nigra (Searle et al.,
2010), although lesser regional D3 selectivity was seen with the antag-
onist ABT-925 (Graff-Guerrero et al., 2010). If one half of our [-
18F]fallypide binding in thalamus (BPND = 0.96) corresponds to D3
receptors, we can then estimate that up to 20% of these sites were occu-
pied by pramipexole in the ON-medication condition. Given a 25% D3
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BPND = 2.2), a 20% occupancy by pramipexole should have reduced
[18F]fallypride binding by 0.4 BPND units.
The lack of discernible occupancy in the extended striatum is
perplexing, and calls for consideration of some limitations of the study.
Medication history or disease state may have attenuated the D3
occupancy by therapeutic pramipexole, although the possibility of a
false negative result in striatum cannot be excluded, given our small
sample size. For logistic reasons, we conducted the ON-pramipexole
scans ﬁrst, without randomization, being unaware of any reports of an
ordering effect on [18F]fallypride binding. Although it might have been
preferable to have obtained individual MR images, our subtraction
of [18F]fallypride BPND maps within individuals, after normalization
to a standard template should accommodate effects of brain atrophy
on the magnitude of Δ-BPND. Although the deterioration in UPDRS
score OFF-medication was less than expected, the study was not de-
signed to conﬁrm the clinical efﬁcacy of pramipexole. Nonetheless, a
pharmacodynamic effect is supported by the release of inhibition of
prolactin secretion at the time of the second PET scan, which correlated
inversely with the residual plasma concentration of pramipexole.
The evidently incomplete clearance of plasma pramipexole, which
remained at a mean of 10% of the therapeutic level during the OFF
medication scan, is consistent with the 13 h plasma half-life reported
in humans (Wright et al., 1997). As such, the possibility of prolonged
retention and action of pramipexole in brain cannot be excluded.
While the occupancy paradigm is well-described in the case of
antipsychotic medications, the corresponding occupancy for dopa-
mine agonist ligands is the subject of only a few studies. The present
ﬁnding of indiscernible effect of pramipexole at a therapeutic dose
on [18F]fallypride binding in striatum, despite signiﬁcant displacement
in substantia nigra and other extra-striatal regions calls for further in-
vestigations of dopamine D3 agonist occupancy in Parkinson's disease
patients and other clinical populations.
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